Kolltan Pharmaceuticals is Drug Discovery in United States that focus on drug candidate business. Founded in 2007. They cover business area such as developer, monoclonal antibody drug, discovery, development, drug candidate, receptor tyrosine kinase, rtk, oncology, immunology, different solid tumor, target KIT, clinical evaluation, cancer, mast cell disease.
2007
( 17 years old in 2024 )
Drug Candidate
-
300 George Street
Suite 530
New Haven, CT 06511
United States
Private
developermonoclonal antibody drugdiscoverydevelopmentdrug candidatereceptor tyrosine kinasertkoncologyimmunologydifferent solid tumortarget KITclinical evaluationcancermast cell disease
* We use standard office opening hours in near Kolltan Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Kolltan Pharmaceuticals is Drug Discovery business from United States that founded in 2007 (17 years old in 2024), Kolltan Pharmaceuticals business is focusing on Drug Candidate.
Kolltan Pharmaceuticals headquarter office and corporate office address is located in 300 George Street Suite 530 New Haven, CT 06511 United States.
Kolltan Pharmaceuticals was founded in United States.
In 2024, Kolltan Pharmaceuticals is currently focus on drug candidate sector.
Above is snippet of Google Trends for "drug candidate" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Kolltan Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
